@article {NewtonP4.396作者= {Braeden d·牛顿和凯蒂·赖特和曼迪·d·温克勒和弗兰西斯卡宝Masaya Takahashi和季米特洛夫伊万·e·玛丽亚Pia索尔和马可·c·Pinho达林·t·奥田硕},title = {3 d形状和表面特征对比多发性硬化症从非特异性脑白质病(P4.396)},体积={88}={16}补充数量,elocation-id = {P4.396} ={2017},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:描述三维(3 d)几何形状和表面特征的多发性硬化症(MS)病变与非特异性白质(NSWM)发现。首页背景:确定结构异常的起源来自NSWM或原位脱髓鞘疾病造成老化,偏头痛,或小血管疾病由传统的二维有限,迫使角度来看,脑损伤的观点。设计/方法:标准化3-Tesla 3 d大脑核磁共振研究进行登记和女士NSWM病人。幕上的局灶性病变,使用最大强度投影重建,手动分割,3 d印刷。打印3 d模型由三个瞎了评级机构评估选定的形状和表面特性。回归模型调整了年龄、疾病持续时间,个别患者效果应用到评估病人团体之间的病变特点。患者的立场和潜类别分析组间进行比较病变表型。结果:共有1001个病灶进行了分析(710毫秒;291 NSWM)确诊的30例(19女士(11女;年龄中位数= 33.6年,范围:26.9 54.5 {\ textendash})),疾病持续时间中值= 2.2年(0.4 19.4 {\ textendash})), 11验证NSWM疾病没有女士(11女;年龄中位数= 55.0年,范围:27.9 {\ textendash} 66.2)。病变来自女士相比NSWM患者表现出更高比例的不对称(75.9 \ %和43 \ %;或者:4.39 (2.37 {\ textendash} 8.12); p\<0.001), complex surface morphologies (65.9\% versus 27.8\%; OR: 2.3 [1.74{\textendash}3.05]; p\<0.001), were multi-lobular (11.0\% versus 0.3\%, p\<0.001), and elongated (12.8\% versus 2.4\%, p\<0.001) in shape. Spatially, asymmetric (p\<0.001), complex surface (p\<0.001), elongated (p=0.001), multi-lobular (p\<0.001), and lesions containing protrusions (p=0.02) were identified at higher frequencies within the juxtacortical, deep white matter, and periventricular regions.Conclusions: Distinct 3D geometric and surface characteristics appear to differentiate lesions resulting from MS and NSWM disease. These data may provide new insights related to the biology of these conditions yielding MRI anomalies along with new approaches to diagnosis and clinical surveillance.Disclosure: Dr. Newton has nothing to disclose. Dr. Wright has nothing to disclose. Dr. Winkler has nothing to disclose. Dr. Bovis has nothing to disclose. Dr. Takahashi has nothing to disclose. Dr. Dimitrov has received personal compensation for activities with Philips Medical Services as an employee. Dr. Sormani has received personal compensation for activities with Novartis, Roche, Genzyme, Merck Serono, Teva, Synthon and Biogen Idec as a speaker and/or consultant. Dr. Pinho has nothing to disclose. Dr. Okuda has received personal compensation for activities with Acorda Therapeutics, Genentech, Inc, Genzyme Corporation, TEVA Neuroscience, EMD Serono, and Novartis. Dr. Okuda has received research support from Biogen.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/88/16_Supplement/P4.396}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }